Our Oncology portfolio is focused on advancing differentiated, science-led therapies across solid tumors and hematological malignancies,
where disease complexity and unmet medical need continue to challenge existing treatment options. The approach combines deep disease understanding,
disciplined science, and global partnerships to support the development of differentiated therapies with meaningful clinical relevance.

Our oncology pipeline reflects our commitment to developing innovative therapies designed to address unmet medical needs across multiple tumor types. Read more